Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity.

Area of Science:

• Pharmacology
• Medicinal Chemistry

Background:

• Ajulemic acid, a synthetic cannabinoid analog, was developed to avoid psychotropic effects.
• Previous studies reported conflicting findings regarding its adverse effects and therapeutic index.

Purpose of the Study:

• To resolve discrepancies in ajulemic acid's adverse effect profile.
• To compare cannabinoid receptor binding affinities of highly purified ajulemic acid with other preparations.

Main Methods:

• Synthesized highly purified ajulemic acid (JBT-101) using a novel method.
• Assessed cannabinoid receptor 1 (CB1) and CB2 binding affinities.
• Evaluated functional responses including catalepsy and hypothermia.

Main Results:

• CB2 binding affinities were consistent across all ajulemic acid samples.
• CB1 binding affinities varied significantly, with JBT-101 exhibiting the weakest affinity.
• The CB1/CB2 affinity ratio differed by 65-fold between JBT-101 and the original HU-239 preparation.
• Functional assays confirmed reduced CB1 activity for JBT-101.

Conclusions:

• The therapeutic index of ajulemic acid requires reevaluation based on the properties of highly purified JBT-101.
• This purified form demonstrates a potentially improved safety profile compared to earlier ajulemic acid preparations.